Raphael Pharmaceutical's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Raphael Pharmaceutical's ROA in the second quarter of 2026?
Raphael Pharmaceutical Inc. recorded a cumulative net loss of $-1 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -194.93%.

However, within the Consumer Non Cyclical sector Raphael Pharmaceutical Inc. achieved the highest return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4716, from total ROA ranking in the first quarter of 2026 at 5422.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	-45.45 %	-97.85 %	27.48 %	-95.24 %	-81.97 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-1	-1	-1	-1	-1
Return On Assets (TTM)	-194.93 %	-213.56 %	-242.23 %	-333.17 %	-341.93 %
RAPH's Total Ranking	# 4716	# 5422	# 4838	# 4906	# 4962
Total Assets (TTM) in million	0	0	2	0	0
Seq. Total Assets Change	500 %	-99.9 %	99650 %	-90.91 %	-76.34 %
Seq. Net Income Change	-	-	-	-	-

RAPH's 5 Years Annual ROA >> Back to RAPH Management Effectiveness >> Compare RAPH ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	#
Sector	#
Overall	# 0

Return On Assets Statistics
High	Average	Low
-499.02 %	-2008.51 %	-5600 %
(Jun 30 2024)		(Jun 30 2026)

Financial Statements
Raphael Pharmaceutical's Assets	$ 0 million	RAPH's Balance sheet
Raphael Pharmaceutical's Income	$ 0 million	Quarterly RAPH's Income Statement
RAPH's Income by Division		See RAPH's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2020) FY 2021
Y / Y Total Assets Change	27.48 %	-3.16 %	51.74 %	121.41 %	-
Total Assets in million	2	2	2	1	0
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-1	-2	-1	-3	-1
Annual Return On Assets	-64.11 %	-97.06 %	-79.46 %	-315.31 %	-149.27 %

RAPH's 5 Years Annual ROA >> Back to RAPH Management Effectiveness >> Compare RAPH ROA to its Competitors

More Return On Assets Ratios
RAPH's' Return on Assets at Yahoo Finance
Legal Cannabis Industry Return On Assets Trends and Statistics
Consumer Non Cyclical Sector Roa Statistics
Roa Trends for overall market
RAPH's Roa Ratio versus Legal Cannabis Industry, Consumer Non Cyclical Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for RAPH's Competitors
Subscribers only: Roa for Raphael Pharmaceutical's Suppliers
Subscribers only: Return On Assets for RAPH's Customers

You may also want to know
RAPH's Roi	RAPH's Inventory Turnover Ratio	RAPH's Growth Rates	RAPH's Dividend Comparisons
	RAPH's Profitability Ratios	RAPH's Asset Turnover Ratio	RAPH's Dividend Growth
RAPH's Roe	RAPH's Valuation Ratios	RAPH's Financial Strength Ratios	RAPH's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Consumer Non Cyclical Sector

ROA

Date modified: 2026-08-17T07:31:59+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.